## Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 4

VERTEX F Form 4 June 02, 20	PHARMACEUTIC	CALS INC	C/MA								
FORM		STATES	SECU	DITIES A		СПАМ	TE COMMISSION		PPROVAL		
	this box	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF									
subject Section Form 4	to <b>STATE</b> 16.	MENT OI	F CHAI	NGES IN SECUI		ICIAL (	OWNERSHIP OF	Estimated average burden hours per response 0			
Form 5 obligati may co <i>See</i> Inst 1(b).	ions Section 17										
(Print or Type	e Responses)										
1. Name and SANDERS	Person <u>*</u>	2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [VRTX]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
		Middle)		of Earliest T Day/Year) 2008	ransaction		X Director Officer (give below)		% Owner her (specify		
	(Street)			endment, D onth/Day/Yea	-	al	Applicable Line) _X_ Form filed by	<ul> <li>6. Individual or Joint/Group Filing(Check</li> <li>Applicable Line)</li> <li>_X_ Form filed by One Reporting Person</li> <li> Form filed by More than One Reporting</li> </ul>			
CAMBRII	DGE, MA 02139						Person	Note than One K	eporting		
(City)	(State)	(Zip)	Tab	ole I - Non-l	Derivative	Securities	s Acquired, Disposed o	f, or Beneficia	lly Owned		
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deem Execution any (Month/Da	Date, if	3. Transactio Code (Instr. 8)	Disposed (Instr. 3,	(A) or of (D) 4 and 5) (A) or	Securities I Beneficially ( Owned ( Following ( Reported Transaction(s) (Instr. 3 and 4)	5. Ownership Form: Direct D) or Indirect I) Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Domindam D	mont on a generate lim	for each -1	on of or-	Code V		(D) Prie					
Kenninder: Ko	eport on a separate line		ass of sec	unues dene	Perso inforr requi	ons who r nation co red to res	respond to the collect ontained in this form spond unless the for rently valid OMB cor	are not m	SEC 1474 (9-02)		

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

number.

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisab Expiration Date (Month/Day/Year		7. Title and A Underlying S (Instr. 3 and	Securities			
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Share			
Stock Option	\$ 28.4	06/01/2008		А	20,000	06/01/2008(1)	05/31/2018	Common Stock	20,000			
Reporting Owners												
	Report	ing Owner Name / A	Address	Relationships								

Х

Director 10% Owner Officer Other

## Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 4

SANDERS CHARLES A C/O VERTEX PHARMACEUTICALS INCORPORATED 130 WAVERLY STREET CAMBRIDGE, MA 02139

## Signatures

Kenneth S. Boger, Attorney-In-Fact 06/02/2008

<u>\*\*</u>Signature of Reporting Person

Date

## **Explanation of Responses:**

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Right to buy under 2006 Stock and Option Plan. Fully vested.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.